secwatch.observer — SEC 8-K summary
======================================

Issuer:     Instil Bio, Inc. (TIL)
CIK:        0001789769
Form:       8-K
Filed at:   2026-05-15T12:30:17+00:00
Accession:  0001789769-26-000044
Event type: earnings
Sentiment:  neutral
Materiality: 0.40
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Instil Bio reports Q1 2026 cash of $74.7M, GAAP net loss per share $0.62
------------------------------------------------------------------------

- Cash, equivalents, restricted cash and marketable securities $74.7M as of March 31, 2026; expected to fund operations beyond 2027.
- GAAP net loss per share $0.62; non-GAAP net loss per share $0.32 for Q1 2026.
- R&D expenses $0.7M (down from $5.4M YoY); G&A expenses $5.3M (down from $9.1M).
- Company actively evaluating potential acquisitions and in-licensing opportunities for novel therapeutic candidates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789769/000178976926000044/0001789769-26-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789769/000178976926000044/til-20260515.htm
  HTML page:      https://secwatch.observer/filing/0001789769-26-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer